CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma.

Autor:	Kassardjian AA; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Ladbury C; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Maraghechi B; Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, USA., Shi C; Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, USA., Watkins T; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Liu A; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Tsai K; Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, USA., Williams T; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Li YR; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Dandapani S; Radiation Oncology, City of Hope National Medical Center, Duarte, USA., Schwer A; Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, USA., Lee P; Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 22; Vol. 16 (8), pp. e67502. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024).
DOI:	10.7759/cureus.67502
Abstrakt:	In the context of oligometastatic renal cell carcinoma (RCC), local treatment with stereotactic body radiotherapy (SBRT) may improve oncologic outcomes. However, the location and size can often pose a technical challenge in standard SBRT delivery, and the dose is potentially limited by nearby organs at risk (OARs). Online adaptive radiotherapy (oART) improves radiation delivery by personalizing high-dose fractions to account for daily stochastic variations in patient anatomy or setup. The oART process aims to maximize tumor control and enhances precision by tailoring to a more accurate representation of a patient in near-real time. The proceeding re-optimization can mitigate the uncertainty inherent in the traditional radiation delivery workflow and precludes the need for larger margins that account for anatomical variations and setup errors. Here, we describe a case of oligometastatic RCC with a bulky (>300 cm 3 ) pleural-based left lower lobe mass extending into the upper abdomen treated via personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR). Three fractions were delivered four weeks apart allowing for tumor shrinkage of these bulky lesions, and oART permitted on-table adaptation of the plan without traditional re-simulation and re-planning required during off-line adaptive radiotherapy. The plan was designed for the Ethos linear accelerator (Varian Medical Systems, Inc., Palo Alto, CA, USA). The prescription dose was 36 Gray (Gy) in three fractions, and the adapted plan was selected in each treatment over the scheduled plan due to better target coverage and reversal of OAR dose violations. The adapted plan met all OAR dose constraints, and it achieved higher target coverage in the first two PULSAR fractions compared to the scheduled plan. In the third fraction, the cumulative point dose was approaching the maximum heart tolerance, and target coverage was accordingly compromised based on clinical judgment. There was evidence of tumor regression throughout the course of treatment, and the patient did not develop any significant radiation-related toxicities. Follow-up imaging has demonstrated the overall stable size of her lesion without any evidence of disease progression. Our case reflects the benefit of adaptive SBRT delivery to a bulky mass near multiple OARs in the setting of oligometastatic RCC. The adapted plan allowed for prioritization of critical structures on a fraction-by-fraction basis while preserving the therapeutic intent of SBRT. Further integration of advanced imaging techniques, optimal disease-specific systemic immunotherapies or targeted therapies, and refinement of patient selection will be crucial in identifying which patients would most benefit from an adaptive approach. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Kassardjian et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu